In:
PLOS ONE, Public Library of Science (PLoS), Vol. 18, No. 1 ( 2023-1-17), p. e0278846-
Abstract:
This meta-analysis aimed to analyze and compare the efficacy and safety of remifentanil and dexmedetomidine applied respectively for controlled hypotension under general anesthesia. We searched the Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, SinoMed, Wanfang, and VIP databases, as well as dissertations and conference papers, to obtain randomized controlled trials comparing remifentanil and dexmedetomidine applied respectively for controlled hypotension before August 23, 2021. The primary outcomes included hemodynamic profiles, surgical field score, and blood loss. Extubation time, sedation and pain score at the PACU, and perioperative adverse events were the secondary outcomes. Nine randomized controlled trials with 543 patients (272 in the dexmedetomidine group and 271 in the remifentanil group) were eventually included. This meta-analysis indicated no significant difference between dexmedetomidine and remifentanil in terms of surgical field score, blood loss, minimum values of mean arterial pressure (MD 0.24 with 95% CI [-1.65, 2.13], P = 0.80, I 2 = 66%) and heart rate (MD 0.42 [-1.33, 2.17], P = 0.64, I 2 = 40%), sedation scores at the PACU (MD -0.09 [-0.69, 0.50], P = 0.76, I 2 = 92%), and incidence of bradycardia (OR 2.24 [0.70, 7.15], P = 0.17, I 2 = 0%). Compared with remifentanil, dexmedetomidine as the controlled hypotensive agent showed a lower visual analogue score at the PACU (MD -1.01 [-1.25, -0.77], P 〈 0.00001, I 2 = 0%) and incidence of shivering (OR 0.22 [0.08, 0.60], P = 0.003, I 2 = 0%), nausea, and vomiting (OR 0.34 [0.13, 0.89], P = 0.03, I 2 = 0%). However, extubation time was shorter in the remifentanil group (MD 3.34 [0.75, 5.93], P = 0.01, I 2 = 90%). In conclusion, dexmedetomidine and remifentanil are both effective in providing satisfactory controlled hypotension and surgical conditions. Dexmedetomidine is better in easing postoperative pain at the PACU and reducing the occurrence of shivering, nausea, and vomiting. Meanwhile, remifentanil is a fast-track anesthesia with a shorter extubation time. Given the limitations of this meta-analysis, further studies are needed for a more definitive comparison of the efficacy and safety of dexmedetomidine and remifentanil.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0278846
DOI:
10.1371/journal.pone.0278846.g001
DOI:
10.1371/journal.pone.0278846.g002
DOI:
10.1371/journal.pone.0278846.g003
DOI:
10.1371/journal.pone.0278846.g004
DOI:
10.1371/journal.pone.0278846.g005
DOI:
10.1371/journal.pone.0278846.g006
DOI:
10.1371/journal.pone.0278846.g007
DOI:
10.1371/journal.pone.0278846.g008
DOI:
10.1371/journal.pone.0278846.g009
DOI:
10.1371/journal.pone.0278846.g010
DOI:
10.1371/journal.pone.0278846.g011
DOI:
10.1371/journal.pone.0278846.t001
DOI:
10.1371/journal.pone.0278846.t002
DOI:
10.1371/journal.pone.0278846.s001
DOI:
10.1371/journal.pone.0278846.s002
DOI:
10.1371/journal.pone.0278846.s003
DOI:
10.1371/journal.pone.0278846.s004
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2023
detail.hit.zdb_id:
2267670-3
Permalink